BPA call order for radioactive pharmaceuticals required for positron emission tomography (pet).
Active Awarded Last action
- Contract number
- HT001426FE014
- Awardee
-
Sofie CO. UEI JV1AHJHGUGG3
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $249,802
Award facts
- Contract value 100% obligated
- $249,801.68 Current and potential, with all options
- Completion date 77% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Bethesda, MD 20889, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency awarded Sofie CO., doing business as IBA Molecular, a BPA call order valued at $249,801.68 on January 15, 2026, for the supply of radioactive pharmaceuticals required for positron emission tomography (PET) imaging. The contract, which carries a firm fixed-price structure with no set-aside designation, is scheduled for completion by January 14, 2027, and will be performed in Bethesda, Maryland. This call order is issued under a larger blanket purchase agreement vehicle established between the Defense Health Agency and Sofie CO., reflecting the agency's ongoing need for specialized diagnostic imaging radiopharmaceuticals to support military treatment facilities.
Sofie CO. is a specialized supplier of molecular diagnostics and therapeutic radiopharmaceuticals with extensive experience serving federal healthcare agencies, including the Department of Veterans Affairs and the National Institutes of Health. The company's product portfolio includes established PET imaging agents such as PYLARIFY (piflufolastat F-18) for prostate cancer detection, NEURACEQ (florbetaben F-18) for Alzheimer's disease imaging, and F-18 fluorodeoxyglucose for general oncology applications. As a subsidiary of Sofie Biosciences, Inc., the company maintains compliance with U.S. Nuclear Regulatory Commission and Food and Drug Administration licensing requirements and has demonstrated sustained competitiveness in the federal radiopharmaceutical procurement market through multiple indefinite delivery contracts and blanket purchase agreements totaling tens of millions of dollars across the VA system and Defense Health Agency.
Quick answers
Who was awarded contract HT001426FE014?
HT001426FE014 was awarded to Sofie CO. by Defense Health Agency (Department of Defense) on January 15, 2026.
How much is contract HT001426FE014 worth?
The government has obligated $249,802 on HT001426FE014.
Is contract HT001426FE014 an order under another contract?
Yes. HT001426FE014 is a BPA call under HT001424A0002, a blanket purchase agreement.
Was contract HT001426FE014 competed?
The extent of competition for HT001426FE014 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award